(Q36313193)

13 August 2017

1 reference

title

The Akt/PKB pathway: molecular target for cancer drug discovery (English)

1 reference

13 August 2017

1 reference

2

Craig W Lindsley

1 reference

13 August 2017

Jin Q Cheng

1

1 reference

13 August 2017

George Z Cheng

series ordinal

3

1 reference

13 August 2017

Hua Yang

series ordinal

4

1 reference

13 August 2017

Santo V Nicosia

series ordinal

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

7482-7492

1 reference

13 August 2017

50

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209088

13 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Mechanism of activation of protein kinase B by insulin and IGF-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Perturbations of the AKT signaling pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PKB binding proteins. Getting in on the Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Strategies to target HER2/neu overexpression for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Synthesis of certain [6:5:6] linear tricyclic nucleosides as potential antitumor agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Antibody humanization: a case of the 'Emperor's new clothes'?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Cellular survival: a play in three Akts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Role for Akt3/protein kinase Bgamma in attainment of normal brain size

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

A Phase II Trial of Tricyclic Nucleoside Phosphate in Patients with Advanced Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PI 3-kinase inhibition: a therapeutic target for respiratory disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

A family with severe insulin resistance and diabetes due to a mutation in AKT2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT/PKB signaling mechanisms in cancer and chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT crystal structure and AKT-specific inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The protooncogene TCL1 is an Akt kinase coactivator

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phage antibodies: filamentous phage displaying antibody variable domains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The Akt pathway: molecular targets for anti-cancer drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PDK1, the master regulator of AGC kinase signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Human cancer, PTEN and the PI-3 kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

D-3-Deoxy-3-substitutedmyo-inositol analogues as inhibitors of cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Opinion: Searching for the elusive targets of farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Small-molecule cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Autophagy in health and disease: a double-edged sword

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

RETRACTED: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT plays a central role in tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Phosphoinositide 3-kinases as targets for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Structural basis for Chk1 inhibition by UCN-01

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209088

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209088

1 reference

13 August 2017

1 reference